IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

REDA, GIANLUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.699
NA - Nord America 3.351
AS - Asia 1.498
SA - Sud America 62
OC - Oceania 18
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.643
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.262
DE - Germania 2.819
GB - Regno Unito 1.011
CN - Cina 699
IT - Italia 697
SE - Svezia 313
SG - Singapore 264
IN - India 179
IE - Irlanda 160
RU - Federazione Russa 134
FR - Francia 127
UA - Ucraina 100
CA - Canada 75
KR - Corea 61
FI - Finlandia 60
JP - Giappone 53
TR - Turchia 53
HK - Hong Kong 48
ID - Indonesia 44
CH - Svizzera 42
EU - Europa 41
NL - Olanda 39
PL - Polonia 38
DK - Danimarca 33
VN - Vietnam 33
ES - Italia 32
CO - Colombia 25
BE - Belgio 23
BR - Brasile 20
GR - Grecia 18
CZ - Repubblica Ceca 15
MX - Messico 12
IR - Iran 11
NZ - Nuova Zelanda 10
AT - Austria 9
IL - Israele 9
AU - Australia 8
TH - Thailandia 8
TW - Taiwan 7
AR - Argentina 6
RO - Romania 6
BG - Bulgaria 5
HR - Croazia 5
HU - Ungheria 5
PH - Filippine 5
CL - Cile 4
MA - Marocco 4
MY - Malesia 4
UY - Uruguay 4
ZA - Sudafrica 4
AM - Armenia 3
PK - Pakistan 3
QA - Qatar 3
A2 - ???statistics.table.value.countryCode.A2??? 2
ET - Etiopia 2
KW - Kuwait 2
LU - Lussemburgo 2
PE - Perù 2
PT - Portogallo 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
IS - Islanda 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
NP - Nepal 1
SC - Seychelles 1
Totale 10.683
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.320
Southend 897
Boise 588
Chandler 375
Hanover 226
Milan 209
Singapore 191
Fairfield 163
Dublin 160
Ashburn 158
Princeton 134
Wilmington 128
Beijing 122
Ann Arbor 98
Woodbridge 95
Seattle 94
Houston 88
Jacksonville 72
Dearborn 66
Cambridge 64
Redwood City 63
Bengaluru 53
Nanjing 53
Des Moines 52
Toronto 51
Payette 45
Shanghai 42
Rome 38
Berlin 37
Garden Valley 37
Helsinki 35
Redmond 30
Warsaw 30
Hong Kong 29
Jerome 29
Jinan 29
Shenyang 29
Phoenix 28
New York 27
Andover 25
Mountain View 25
Orofino 24
Brussels 23
Nanchang 22
Boardman 21
Cottonwood 21
Guangzhou 21
Jakarta 20
Bogotá 19
Lewiston 19
Los Angeles 19
Kent 18
Mumbai 18
Sakarya 18
Tokyo 18
Turin 18
Deiva Marina 17
Hyderabad 17
Santa Clara 17
Genoa 16
Seoul 16
Serra 16
Fuzhou 15
Kiez 15
Tianjin 15
Changsha 14
San Diego 14
Athens 13
Grafing 13
Hebei 13
Central District 12
Genova 12
Hefei 12
Nordman 12
Polcenigo 12
Somerville 12
Dong Ket 11
Roxbury 11
San Jose 11
Ankara 10
Brno 10
Duncan 10
Fremont 10
Madrid 10
San Francisco 10
Bitonto 9
Chengdu 9
Hangzhou 9
São Paulo 9
Wuhan 9
Bari 8
Pavia 8
Silver Spring 8
Bühl 7
Kunming 7
London 7
Montereale Valcellina 7
Munich 7
Ponderay 7
Quanzhou 7
Totale 7.828
Salva come PNG Salva come JPEG
Nome #
Low dose dasatinib in refractory imatinib mesylate chronic myeloid leukemia : case report 934
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for del(5q) Myelodysplastic Syndrome 333
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials 330
Assessment of the 4-factor score : Retrospective analysis of 586 CLL patients receiving ibrutinib : A campus CLL study 323
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia : a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 290
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases 273
FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T cell acute lymphoblastic leukemia 262
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL) : results of a prospective, single-arm multicentre study 251
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases 237
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 220
Ineffective hematopoiesis and markers of angiogeneisis in myelodysplastic syndromes 218
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) 208
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia : a GIMEMA multicenter phase II trial 202
Acute idiopathic polyneuropathy after subcutaneous alemtuzumab (AL) therapy in chronic lymphocytic leukemia (CLL) patients 200
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes 197
Guillain Barrè syndrome in a chronic lymphocytic leukaemia (CLL) patient after subcutaneous alemtuzumab (A) therapy 195
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 193
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia 192
Evalutation of TIE2-expressing monocytes in myeloid disorders 190
Lenalidomide in the treatment of chronic lymphocytic leukemia 183
Iron metabolism and erythropoietic stress in myelodysplastic sindrome 180
Hepcidin levels and their determinants in different types of myelodysplastic syndromes 180
Biological and molecular characterization of a rare case of cutaneous Richter syndrome 173
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 166
Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report 165
Low dose campath 1-H is highly effective and safe in advanced chronic CLL 162
Relationship between expression of TLRS and disease activity in B-CLL 160
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 158
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 157
Conjunctival hemorrhagic events associated with imatinib 154
Myelodysplastic syndromes : microvascular density and immunohistochemical expression of the proteins controllin angiogenesis 154
Role of dasatinib in PH '-positive acute lymphoblastic leukemia (ALL) after imatinib-based therapy failure : a case report 152
Low-dose subcutaneous campath (CAM) is highly effective and safe in advanced and chemotherapy-refractory B-CLL : results of a prospectic and multicenter phase II study 143
Low-dose ALEMTUZUMAB monotherapy in advanced chronic lymphocytic leukemia 143
Conjunctival hemorrhagic events associated with imatinib mesylate 142
Low-dose Alemtuzumab in Refractory/Relapsed Chronic Lymphocytic Leukemia : Genetic Profile and Long-term Outcome from a Single Center Experience 141
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 141
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion : results from the National Registry of the Italian Drug Agency 139
Predictors of atrial fibrillation in ibrutinib-treated CLL patients : a prospective study 137
Efficacy of front-line ibrutinib and rituximab combination and the impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia : results of the Gimema LLC1114 Study 134
Fludarabine-Ifosfamide-Rituximab (FIR): a therapeutic option for chronic lymphocytic leukemia patients resistant to Chlorambucil 129
Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations 126
Reduced expression of toll-like receptor 4 in B-chronic lymphocytic leukemia patients with autoimmune complications 126
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 120
Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia 119
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation 118
Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome 116
Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia 113
New SMAC-Mimetic Compounds Strongly Induce In Vitro Apoptosis of Human Lymphocytes From Patients with Chronic Lymphocytic Leukemia 113
Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL) 111
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 109
Impact of bone marrow fibrosis in response to azacitidine in 94 patients with myelodisplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia 108
Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia 107
Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature 107
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia 100
Chronic lymphocytic leukemia and prognostic models : a bridge between clinical and biological markers 96
Expression of TLRs in B-CLL: Relationship with Disease Activity 95
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 86
Secondary malignancies in chronic lymphocytic leukemia: a single centre retrospective analysis 86
Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases 81
Heminsight to assess patient reported outcomes of patients affected by chronic lymphocytic leukemia in daily clinical practice 78
Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A Predictor of Outcome? 73
Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice? 65
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 64
Hypogammaglobulinemia is a strong predictor of time to first treatment in chronic lymphocytic leukemia 63
Lymphocytic infiltrate and p53 protein expression as predictive markers of response and outcome in myelodysplastic syndromes treated with azacitidine 51
null 6
Totale 11.078
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020694 0 0 0 85 56 64 99 38 116 144 64 28
2020/20211.292 87 77 149 48 99 130 66 91 156 102 190 97
2021/20221.373 113 92 266 62 92 59 72 92 133 93 87 212
2022/20231.490 186 145 140 154 132 250 43 92 185 33 87 43
2023/20242.431 38 78 75 55 169 120 359 332 177 318 357 353
2024/20251.261 342 413 248 258 0 0 0 0 0 0 0 0
Totale 11.078